Therapure Innovations, a division of Therapure Biopharma Inc., received approval from the FDA to proceed with a Phase I trial of TBI 302, a targeted therapeutic for the treatment of liver cancer. The Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics of TBI 302 following administration to patients with advanced liver cancer.   TBI 302 is the first drug from Therapure’s targeted drug delivery platform. It leverages the natural clearance pathway of hemoglobin predominantly t...